The present invention provides a composition, comprising: proaccelerin (factor V) and at least one factor selected from the group consisting of: prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X), wherein an amount of the proaccelerin in the composition is between 75% to 750% compared to an amount of proaccelerin in a blood plasma, and wherein an amount of the at least one factor is from 150% to 3000% compared to an amount of the at least one factor in the blood plasma; wherein the amount of proaccelerin and the at least one factor in the composition is determined by extrapolating an observed activity of the composition at a concentration of 500 mM NaCl, using a prothrombin complementation assay using a standard curve constructed using the blood plasma.

In some embodiments, the present invention provides compositions including silk fibroin, at least one hydrophilic agent, and at least one catechol donating agent, wherein the at least one hydrophilic agent and at least one catechol donating agent are conjugated to the silk fibroin. According to various embodiments, at least a portion of the silk fibroin may be crosslinked. In some embodiments, the silk fibroin is at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or more) crosslinked. In some embodiments, the present invention also provides methods for making such compositions.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks.

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.

Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage.

The present invention provides a biodegradable medical adhesive or a sealant composition containing an oxidized glycosaminoglycan and a polyamine. The composition of the present invention exhibits improved effects in biodegradation, coating property, gelation time, hemostatic capacity, adhesive force, moisture absorptive capacity and the like, and thus can be applied to various medical uses in which a medical adhesive or sealant can be used, such as biotissue adhesion, filling, coating, adhesion prevention, wound covering, leakage prevention and hemostasis.

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone.

The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.